Results 131 to 140 of about 1,701 (184)

Long-Acting Cabotegravir/Rilpivirine, Lenacapavir, and Ibalizumab Use Among Persons With HIV-1 Viremia at a Ryan White-Funded Clinic in the Urban US South. [PDF]

Clin Infect Dis
Colasanti JA, Aldredge A, Niles-Carnes LV, Ochieng E, Pareek P, Robinson V, Anderson E, Castaneda M, Spralling H, Smith BL, Sumitani J, Paul Leue E, Moran CA, Lora M, Armstrong WS, Collins LF.   +15 more
europepmc   +1 more source

Combined injectable regimens in treatment-experienced HIV/AIDS patients at a southern academic medical center: a case series. [PDF]

BMC Infect Dis
Burton HJ, Rivere E, Kirk S, Berry H, Lueking R.   +4 more
europepmc   +1 more source

Research progress on HIV-1 structural proteins and antiviral therapies. [PDF]

Front Immunol
Wang H, Yuan J, Wang H.
europepmc   +1 more source

Baseline and week 48 resistance analysis in participants receiving bictegravir + lenacapavir in the phase 2 ARTISTRY-1 study. [PDF]

AIDS
Pennetzdorfer N, Naik V, Montezuma-Rusca JM, Sklar P, Callebaut C, Margot NA.   +5 more
europepmc   +1 more source

Accelerating Subcutaneous Drug Development: A Mechanistic Absorption Model for the Open Systems Pharmacology Framework. [PDF]

CPT Pharmacometrics Syst Pharmacol
Pellowe M, Dubbelboer I, Sjögren E.
europepmc   +1 more source